- Home
- GORO vs MAIA Comparison
GORO vs MAIA Comparison
Compare GORO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GORO | MAIA |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 49.3M |
| IPO Year | 2010 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GORO | MAIA |
|---|---|---|
| Price | $1.42 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.75 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,726,000.00 | N/A |
| Revenue This Year | $9.04 | N/A |
| Revenue Next Year | $93.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.87 |
| 52 Week High | $1.87 | $3.19 |
Technical Indicators
Market Signals| Indicator | GORO | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 39.59 |
| Support Level | $1.27 | $1.20 |
| Resistance Level | $1.75 | $1.69 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 28.00 | 17.13 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.